The Weekly Summary

July 16th – July 22nd                                 2018

In general news, Presidents Trump and Putin met for secret discussions in Helsinki. The U.S. opposition criticized Trump for being too soft on Putin. Then, the entire narrative of the Trump opposition broke down when the FISA court briefs, used by Obama’s DOJ to gain permission from a judge to surveil the Trump campaign, were made public.

In healthcare business news, JNJ, ABT, and others reported earnings. Pfizer, PFE), Merck (MRK), and Novartis (NVS) backed away from planned drug hikes after President Trump implemented a plan to lower drug prices. NVS also licensed from Galapagos (GLPG) and MorphoSys (MOR) a prospective drug to treat atopic dermatitis.

On the data front, Lily (LLY) and PFE met endpoints for anti-NGF pain drug tanezumab.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.